



an Open Access Journal by MDPI

International Journal of Translational Medicine

A close-up photograph of several orange liquid droplets on a light-colored surface, creating a textured, bubbly appearance.

[mdpi.com/
journal/
ijtm](http://mdpi.com/journal/ijtm)



Message from the Editor-in-Chief

International Journal of Translational Medicine (ISSN 2673-8937) is an international, peer-reviewed, open access journal that welcomes submissions from researchers, clinicians, policymakers, and the industry. It publishes reviews, regular research papers, short communications, and case reports. There is no restriction on the maximum length of the papers. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental and/or methodological details must be provided for research articles.

Editor-in-Chief

Prof. Dr. Pier Paolo Claudio

Aims

The *International Journal of Translational Medicine* (ISSN 2673-8937) is an international, peer-reviewed, open access journal on Translational Medicine. Our aim is to provide space to those studies that start from a clinical question, address it by transitioning to the bench, and then translate the solution to the bedside once the original clinical question is solved.

We encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, the journal has no restrictions regarding the length of papers. Full experimental details should be provided so that the results can be reproduced.

Manuscript categories: original scientific research articles, comprehensive reviews, communications, case reports, letters, commentaries, editorials, etc.

Scope

The *International Journal of Translational Medicine* emphasizes the clinical applicability of new biomaterials, biotechnologies, biomarkers, diagnostics, omics science, molecular medicine, bioinformatics, immunology, molecular imaging, drug discovery and development, population health, infectious diseases, gene therapy, stem cells, disease pathology and treatment.

Author Benefits

Open Access

Unlimited and free access for readers

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 24.2 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2024)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

ijtm@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

January 2025

